Prefilled Syringes Market

Prefilled Syringes Market Forecast and Outlook By Fact.MR

In 2025, the Prefilled Syringes market was valued at USD 9.8 billion. Based on Fact.MR analysis, demand for prefilled syringes is estimated to grow to USD 10.5 billion in 2026 and USD 20.8 billion by 2036. Fact.MR projects a CAGR of 7.1% during the forecast period.

This USD 11.1 billion increase reflects steady, incremental growth rather than transformational expansion, supported by rising adoption of biologics and increased shift toward self-administration. Growth remains moderated by structural constraints such as high regulatory and sterility compliance costs, fill-finish capacity limitations, material supply sensitivities (glass and advanced polymers), and substitution pressure from autoinjectors and other advanced drug delivery systems. As Tom Polen, Chairman, CEO, and President of Becton, Dickinson and Company, noted regarding hospital efficiency and technology adoption, 'solutions that drive automation and efficiency' help providers manage costs.

Summary of Prefilled Syringes Market

• Market Snapshot
  • Global prefilled syringes market revenue stood at USD 9.8 billion in 2025 and is forecast to reach USD 20.8 billion by 2036.
  • At a 7.1% CAGR from 2025 to 2036, this market is set to expand 2.0x in value, adding USD 9.7 billion in absolute opportunity.
  • Growth is being driven by increasing demand for advanced drug delivery solutions and rising adoption in pharmaceutical manufacturing systems.
  • Prefilled syringes are gaining traction as efficient drug delivery systems, improving patient safety, dosing accuracy, and reducing administration complexity.
• Demand and Growth Drivers
  • Increasing demand for drug delivery solutions across pharmaceutical and healthcare sectors is driving adoption.
  • Rising focus on patient safety optimization and reduction of medication errors is accelerating market growth.
  • Growing penetration of prefilled syringes in specialized healthcare applications is expanding the addressable market.
  • Expansion of pharmaceutical manufacturing capabilities and advanced drug delivery technologies is supporting long-term growth.
  • Product and Segment View
  • Safety Prefilled Syringes holds 63.4% of material share in 2026, emerging as the leading segment due to strong compatibility and regulatory acceptance.
  • Key product categories include:
    • Glass Prefilled Syringes
    • Plastic Prefilled Syringes
• Geography and Competitive Outlook
  • Growth is supported across major regions including North America, Europe, and Asia Pacific.
  • Market expansion is closely tied to:
    • Increasing pharmaceutical production
    • Expansion of healthcare infrastructure
    • Rising adoption of advanced drug delivery systems
  • Key companies active in this market include: Gerresheimer, SCHOTT, BD, Nipro, West Pharma, Terumo, Stevanato, Weigao, Ompi.

Prefilled Syringes Market — At a Glance

Source: Fact.MR analysis, based on proprietary forecasting model and primary research

Segmental Analysis

Prefilled Syringes Market Analysis by Product Type

Based on Fact.MR's Prefilled Syringes market report, consumption of safety prefilled syringes holds 63.4% share in 2025. The reason behind the dominance is that it has natural safeguards against needlesticks. This is one of the most important factors when it comes to regulation and operations in the healthcare sector. It is also more structurally sound as it helps maintain safety standards without any liabilities.

• Capacity Investment: Becton, Dickinson and Company (BD) announced an USD 110 million investment in August 2026 to expand its U.S. manufacturing footprint for prefillable syringes, including BD Neopak production in Nebraska [2]. This investment highlights ongoing efforts to strengthen domestic supply chains and meet rising demand for biologics-compatible delivery systems.
• Technology Advancement: In January 2026, BD and Ypsomed expanded their partnership to develop a 5.5 mL BD Neopak XtraFlow glass prefillable syringe compatible with the YpsoMate autoinjector platform, specifically targeting large-volume biologics [3]. The system incorporates thinner cannulas and shorter needles to improve flow and injection time, addressing limitations of conventional syringe formats.
• Supply Chain Expansion: Gerresheimer is expanding its Wertheim site with a new production facility for ready-to-fill pharmaceutical containers, strengthening its capacity to serve global pharma customers and biologics demand [4]. This reflects a broader industry shift toward scaling high-quality primary packaging infrastructure to support long-term supply agreements.

Prefilled Syringes (PFS) Production and Supply

Prefilled syringe production in the world is being carried out more by a consortium of large pharmaceuticals CDMOs and special device producers with the top 10 manufacturers controlling around 55% of total capacity. Capital investment in manufacturing is huge due to aseptic filling lines, which costs between USD 8-15 million per line depending on automation and size of the machine (nest-and-tub vs. bulk). Glass prefilled syringes remain the dominant form of delivery, but polymeric forms are growing in significance due to breakable nature and biological products compatibility.

The manufacturing process of prefilled syringes is very complex, and there is no single player involved; instead, there are primary packaging makers (barrel, plunger, stopper), fill-finish companies, and pharmaceutical companies working in a synchronized production cycle. As indicated in the survey by Fact.MR, post-COVID situation, lead times in PFS manufacturing are around 4-6 months although capacity tightness still occurs because of biological demand growth. North America and Europe contribute around 60% to worldwide production, but now Asia (China and India) is becoming a fast-growing region, with 10-15% yearly capacity increase.

Regulatory Complexity & Approval Timelines (US FDA, EMA, CDSCO)

Regulatory pathways are one of the top barriers to success in the prefilled syringes (PFS) market, affecting product time-to-market, cost structures, and partnerships. For instance, in the U.S., the PFS should be approved by the USFDA, being a combination of drug and device, therefore following strict guidelines related to both CDER and CDRH. Typically, such approval requires 12–18 months, which can be even prolonged for biologic drugs due to the necessity of providing stability studies and E&L data.

In Europe, the PFS is required to go through the central procedure regulated by the European Medicines Agency. However, the variability associated with the presence of device-related parts leads to extended approval processes for an average of 12–24 months. The new Medical Device Regulation (MDR) is expected to bring additional challenges, including increased documentation requirements and higher costs, accounting for approximately 15–25%. The Indian regulator of prefilled syringes, the Central Drugs Standard Control Organisation- provides faster paths to approval, up to 6–12 months. However, more stringent demands can be expected concerning locally manufactured biologic drugs and those targeting international markets. According to the study, more than 65% of the market's producers view regulatory alignment as one of the biggest obstacles on their way to the global stage.

Prefilled Syringes Market Analysis by Application

Based on Fact.MR's Prefilled Syringes market report, consumption of diabetes is estimated to hold around 41.2% share in 2025. In this regard, this segment dominates because of the recurrent and high requirement for insulin shots, which demand a handy and accurate way of administering the drug. One of the structures that can facilitate this process is the pre-filled syringe, which is structured to solve this problem efficiently.

• Demand for Diabetic Care: As there is an increased presence of diabetes globally, the demand for prefilled syringes is being fueled because patients have to take frequent doses of the medicine. This makes it necessary for them to administer insulin injections regularly, which are easy with prefilled syringes.
• Patient Preference for Self-Administration: Since more and more people want self-administration for their diseases, it is leading to greater adoption of prefilled syringes. There is greater convenience associated with these as patients have to go through less trouble of getting trained on their use.
• Compatibility with Biologics: Injectable biologic drugs have been introduced as treatments for metabolic diseases, and hence there is a growing need for compatibility with such medicines.

Prefilled Syringes Market Analysis by Material

Glass is projected to account for 72.0% of the prefilled syringes market in 2025 by material, reaffirming its position as the category's dominant material type. Medical device manufacturers increasingly recognize the optimal balance of performance and cost-effectiveness offered by glass systems for most pharmaceutical applications, particularly in drug delivery and healthcare optimization processes.

Glass forms the foundation of most pharmaceutical protocols for healthcare applications, as it represents the most widely accepted and commercially viable level of drug delivery technology in the industry. Performance control standards and extensive medical testing continue to strengthen confidence in glass formulations among pharmaceutical and healthcare providers.

With increasing recognition of the cost-performance optimization requirements in pharmaceutical production, glass systems align with both operational efficiency and drug delivery reliability goals, making them the central growth driver of comprehensive healthcare strategies.

Regional Analysis

The report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and the Middle East & Africa. Geographic segmentation of the market can be done considering regional consumption trends, healthcare framework, and regulatory scenarios. In addition to that, the report includes the market attractiveness study.

CAGR Table Prefilled Syringes Market

North America

This is one of the leading markets in the application of advanced drug delivery, owing to the presence of robust pipelines of biologics and stringent safety norms. Some of the prominent companies in this market include Becton, Dickinson and Company – market leader with diversified range of prefillable syringes and safety systems, West Pharmaceutical Services, Inc., key player offering quality injectables and containment solutions, Catalent, Inc.

• United States: Demand for prefilled syringes in the United States is projected to rise at 6.4% CAGR through 2036. Growth is supported by continued regulatory momentum, including FDA approvals of new biologics in prefilled syringe formats (multiple approvals, 2025), reinforcing adoption of ready-to-use delivery systems.
• Canada: Demand for prefilled syringes in Canada is projected to rise at 7.2% CAGR through 2036. Growth is mainly attributed to the increase in utilization of biologics and preference for self-injection by patients suffering from chronic diseases. Other factors contributing to the growth include harmonization of Canada's device standards with international standards and stable public health-care procurement systems in Canada despite slow growth because of an established healthcare system.

Western Europe

The region plays a central role in setting stringent safety and quality standards for prefilled syringes, driven by strong regulatory frameworks and advanced pharmaceutical manufacturing. Key players include Gerresheimer AG, a leader in high-quality glass and polymer syringe systems, SCHOTT Pharma AG, known for premium drug containment solutions for biologics, and Stevanato Group, which holds a strong position in integrated drug delivery and fill-finish solutions.

• Germany: Demand for prefilled syringes in Germany is projected to rise at 4.4% CAGR through 2036. Growth is supported by the country’s Statutory Health Insurance (SHI) system, which continues to reimburse advanced injectable therapies and associated delivery formats, ensuring steady adoption of prefilled systems. EU Medical Device Regulation (MDR) updates impacting Germany (March 2026) are reinforcing stricter safety and quality requirements, driving preference for high-quality, compliant prefilled syringe systems.
• United Kingdom: Demand for prefilled syringes in the United Kingdom is projected to rise at 5.1% CAGR through 2036. Growth is driven by public healthcare deployment, including NHS Accelerated Access Collaborative programs that fast-track adoption of advanced drug delivery technologies. UK government updates to medical device regulations aligned with EU frameworks (March 2026) are strengthening compliance requirements, supporting uptake of safer and more efficient prefilled systems.
• France: Demand for prefilled syringes in France is projected to rise at 5.4% CAGR through 2036. Expansion will be driven by robust reimbursement structures for biologics and injectables within France’s national healthcare system, promoting usage of cutting-edge dosage forms. The adherence of manufacturers to the scientific guidelines of the European Medicines Agency (EMA) with respect to drug/device combinations is expected to continue to drive growth in the market.

South Asia and ASEAN

India leads with a CAGR of 10.9%, driven by rapid expansion of biologics access and a large patient pool, followed by China at 8.6% due to strong domestic manufacturing and rising chronic disease burden, Brazil at 7.4% supported by expanding public healthcare and vaccine demand, and Japan at 6.6% owing to its aging population increasing injectable drug usage, meanwhile, mature markets including the U.S. (6.4%), France (5.4%), the UK (5.1%), and Germany (4.4%) exhibit comparatively slower growth as they are largely driven by replacement demand rather than new adoption, with growth constrained by high regulatory and compliance costs.

According to Fact.MR, the market analysis of prefilled syringes in North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and Middle East & Africa comprises individual country analysis including the USA, Canada, Mexico, Brazil, Germany, the UK, France, Russia, China, Japan, India, and GCC countries. The readers will get detailed information regarding the regional demand patterns and growth rate of each individual market segment.

Key Takeaways

• Market Definition: The prefilled syringes market comprises ready-to-use injection devices preloaded with precise doses of medication, designed to improve safety, dosing accuracy, and ease of administration across clinical and homecare settings.
• Demand Drivers:
  • Rising use of biologic drugs for chronic conditions such as rheumatoid arthritis and cancer is increasing demand for precise, sterile delivery formats like prefilled syringes.
  • Growth in self-administration trends, especially among diabetes and autoimmune patients, is driving adoption of user-friendly, ready-to-inject systems.
  • Expansion of global vaccination programs and emergency stockpiling is boosting demand for prefilled formats that reduce preparation time and dosing errors.
• Key Segments Analyzed:
  • By Product Type: Safety prefilled syringes lead, accounting for over 60% share due to regulatory push for needlestick injury prevention.
  • By Application: Diabetes and autoimmune diseases dominate, supported by high-frequency injection requirements.
  • By Geography: North America leads with ~40% share, driven by advanced biologics adoption and healthcare infrastructure.
• Analyst Opinion at Fact.MR:
  • Senior Consultants at Fact.MR opines that, 'CXOs will find that long-term value lies in integrating safety features and aligning with biologics-driven demand while managing cost and compliance pressures'.'
• Strategic Implications / Executive Takeaways:
  • Invest in safety-engineered and autoinjector-compatible syringe platforms to align with evolving regulatory and patient usability requirements.
  • Expand fill-finish and sterile manufacturing capacity to address supply bottlenecks in biologics delivery.
  • Strengthen partnerships with pharmaceutical companies to integrate drug-device combination offerings and secure long-term contracts.
• Methodology:
  • Data triangulated using primary interviews with industry stakeholders and secondary sources such as company filings and regulatory databases.
  • Market estimates validated through cross-verification of production capacities, pricing trends, and regional consumption patterns.
  • Forecasts updated periodically based on new product launches, regulatory changes, and shifts in end-use demand.

Drivers, Restraints, and Opportunities

Transformation from Generic to Compliant Driven Industry Unfolds New Opportunity

According to Fact.MR analysts, the global market for prefilled syringes has transformed from a specialized packing type to an organically developing and regulatory-compliant segment amid the larger landscape of the injectable drugs delivery industry. The present market value of this product category is driven by the emergence of biological drugs and treatments for chronic diseases, necessitating high precision, sterility, and repeatability in dosage forms. Moreover, the need for protecting healthcare professionals against needlestick injuries and ensuring the safety of medications has spurred the migration from traditional vial packs to prefilled syringes. Adoption accelerates when pharmaceutical companies shift from vial-based formats to ready-to-use delivery systems to reduce preparation time, contamination risk, and operational complexity.

Fact.MR analysts observe a clear shift from standard, low-cost glass prefilled syringes toward advanced, safety-engineered and biologics-compatible systems. Demand for conventional formats is gradually softening, particularly in mature hospital settings where safety regulations and automation are reducing their relevance. Prefilled syringes face substitution pressure from autoinjectors and pen injectors, particularly in homecare settings requiring ease of use.

On the other hand, there are increased growth being recorded in value-added products like dual chamber syringes, polymeric syringes, and auto-injector compatible syringes due to the application in biological drugs and home care applications. Even though these syringes cost more on a unit basis, they are used in smaller amounts because of their unique applications. As a result, the revenue increase offsets the limited volume increase.

• Biologics Expansion: The fast proliferation of monoclonal antibodies and other biologics products creates more structural demand for syringes that are able to accommodate highly viscous medicines with specific dosing needs. As distinct from small molecules, biologics need special mechanisms for delivery, thus forcing companies to manufacture syringes capable of this task. As a result, the per-unit value grows dramatically.
• Regulatory Safety Mandates: Policies such as the U.S. Needlestick Safety and Prevention Act and the EU Sharps Directive (2010/32/EU) are accelerating adoption of safety-engineered syringes [1]. These regulations require healthcare providers to reduce needle-related injuries, forcing a transition away from conventional syringes. As compliance becomes mandatory, safety syringes command higher pricing and dominate procurement decisions.
• Asia Manufacturing Shift: Developing countries such as China and India have emerged as vital production and consumer centers for several reasons, including cost savings and growth in their respective pharmaceutical markets. The rise in local production facilities and health care accessibility has led to an increase in regional consumption of prefilled syringe systems.

Where Opportunities Underlying in Global Prefilled Syringes Market

The prefilled syringes market represents a specialized growth opportunity, expanding from USD 9.8 billion in 2025 to USD 20.8 billion by 2036 at a 7.1% CAGR. As healthcare providers prioritize patient safety, regulatory compliance, and treatment efficiency in complex drug delivery processes, prefilled syringe systems have evolved from a niche pharmaceutical technology to an essential component enabling healthcare optimization, drug monitoring, and multi-stage delivery across pharmaceutical operations and specialized medical applications. Fill-finish capacity constraints act as a structural bottleneck, creating pricing power for suppliers with sterile manufacturing capabilities.

The convergence of healthcare expansion, increasing drug delivery optimization adoption, specialized pharmaceutical organization growth, and patient safety monitoring requirements creates sustained momentum in demand. High-efficiency formulations offering superior prefilled syringe performance, cost-effective glass material systems balancing performance with economics, and specialized plastic variants for critical applications will capture market premiums, while geographic expansion into high-growth Asian pharmaceutical markets and emerging market penetration will drive volume leadership. Regulatory emphasis on healthcare adoption and drug delivery performance provides structural support.

• Glass Material Dominance: Leading with 72.0% market share, glass materials drive primary demand through complex pharmaceutical workflows requiring specialized prefilled syringe systems for healthcare optimization. Advanced formulations enabling improved drug stability, reduced contamination risks, and enhanced patient safety command premium pricing from healthcare providers requiring stringent performance specifications and regulatory compliance. Expected revenue pool: USD 11.5-15.2 billion.
• Diabetes Market Leadership: Dominating with 41.2% market share through an optimal balance of performance and cost-effectiveness, biologics serve most pharmaceutical applications while meeting prefilled syringe requirements. This specification addresses both performance standards and economic considerations, making it the preferred choice for pharmaceutical production and healthcare operations seeking reliable performance. Opportunity: USD 7.0-9.0 billion.
• American Market Acceleration: USA (6.4% CAGR) and Canada (7.2% CAGR) lead global growth through pharmaceutical infrastructure expansion, drug delivery capability development, and domestic prefilled syringe demand. Strategic partnerships with local pharmaceutical manufacturers, regulatory compliance expertise, and supply chain localization enable the expansion of drug delivery technology in major healthcare hubs. Geographic expansion upside: USD 3.5-5.0 billion.
• Single-chamber Design Growth: Accounting for 74.0% of design demand, single-chamber systems represent high-growth opportunities in standard drug delivery markets. Companies developing advanced single-chamber formulations, supporting pharmaceutical initiatives, and expanding into healthcare-focused markets capture premium demand from pharmaceutical manufacturers and specialized healthcare organizations. Market expansion potential: USD 4.8-6.5 billion.
• European Market Leadership & Supply Chain Excellence: Germany (4.4% CAGR) and U.K. (5.1% CAGR) lead European expansion through specialized distribution networks, strategic inventory management, and reliable supply systems. Companies offering guaranteed supply security, technical support, and regulatory documentation gain preferred supplier status with compliance-focused healthcare providers across developed markets. European opportunity: USD 2.8-4.0 billion.

Competitive Aligners for Market Players

The prefilled syringes market exhibits a moderately consolidated structure, with the top 5 players accounting for an estimated approximately 55% of global revenue. Companies such as Becton, Dickinson and Company, Gerresheimer AG, and SCHOTT Pharma AG enjoy the competitive edge of size and experience in their pharmaceutical partnerships. Quality and compliance emerge as the key factor in competition, followed closely by supply reliability and compatibility with biologicals, not price.

The structural advantage of the industry lies in firms that offer the combination of design and production as well as fill-finish expertise. Such companies as Stevanato Group possess a vertical advantage by having integrated capabilities for packaging and engineering. Companies with stable contracts with major pharmaceutical firms also have the competitive edge due to their assured demand and the difficulty involved in switching, especially when biological products require lengthy and expensive validation processes.

Switching costs are high, and buyers exhibit risk aversion since pharmaceutical firms favor suppliers who have been tested. Buyers can reduce their dependency on suppliers through dual sourcing and long-term contracts. Although this constrains the supplier from increasing prices quickly, suppliers that have shown their ability to comply and possess special skills maintain some degree of pricing power, particularly in the expensive biologics category where there are limited qualified substitutes.

Recent Developments

• Gerresheimer Product & Platform Launch (January 2026): Gerresheimer AG showcased its EZ-fill Smart ready-to-fill platform and Gx Elite syringe systems at Pharmapack 2026, targeting biologics and homecare delivery applications [Gerresheimer].
• Fresenius Kabi expanded its Simplist® portfolio of prefilled syringes in December 2025 with the launch of ephedrine sulfate and succinylcholine chloride injections, extending its use into operating room and anesthesia settings [Fresenius Kabi].
• BD Capacity Investment (August 2025): Becton, Dickinson and Company announced a USD 35 million investment to expand prefilled syringe production at its Nebraska facility, strengthening U.S. supply capacity for injectable therapies [BD].

Key Players in the Global Prefilled Syringes Market

• Becton, Dickinson and Company (BD)
• Gerresheimer AG
• SCHOTT Pharma AG
• West Pharmaceutical Services, Inc.
• Stevanato Group
• Terumo Corporation
• Nipro Corporation
• Baxter International Inc.
• AptarGroup, Inc.
• B. Braun SE
• Catalent, Inc.
• Vetter Pharma International GmbH
• Credence MedSystems, Inc.
• Weigao Group
• Fresenius Kabi

Report Scope

Bibliography

• [1] European Commission
  • “Directive 2010/32/EU on prevention of sharps injuries in the hospital and healthcare sector”
  • (Referenced regulatory framework, active in current compliance context)
• [2] Becton, Dickinson and Company (BD) - “BD announces $110 million investment to support U.S. pharmaceutical supply chain”, August 2026
• [3] Ypsomed Group - “Ypsomed and BD expand partnership to advance self-injection systems for large volume biologics”, January 2026
• [4] Gerresheimer AG (EQS News) - “Gerresheimer expands Wertheim site with new production facility for ready-to-fill vials”, January 2026
• [5] Gerresheimer AG - “Gerresheimer at Pharmapack 2026: Innovative solutions for biopharmaceuticals and adherence support”, January 2026
• [6] Contract Pharma - “Fresenius Kabi expands Simplist portfolio of prefilled syringes”, December 2025
• [7] Becton, Dickinson and Company (BD) - “BD to invest $35 million in Nebraska facility to expand prefilled flush syringe manufacturing”, August 2025

Prefilled Syringes Market Definition

The global prefilled syringes market covers a predetermined dosage of medicine without the requirement for filling manually prior to administration. The aim of the products are mainly focused on the delivery of injectable medicines with ease and safety. The main purpose of using the devices is to deliver medications through injection. In addition, prefilled syringes can be used for biopharmaceuticals and long-term illness treatment. Main applications include diabetes management, autoimmune disorders, vaccination, among others.

Prefilled Syringes Market Inclusion

The report covers global and regional market sizes for the prefilled syringes market, with forecasts spanning 2026 to 2036. It presents segment analysis by different categories such as product type, applications, end-users, and others. The report also offers other analytical parameters like pricing analysis, import-export, and competition analysis. It helps in understanding the overall structure of the market and future growth potential in the market.

Prefilled Syringes Market Exclusion

The report does not include devices that deliver drugs independently, including autoinjectors, pen injectors, and wearable injectors where they are not attached to prefilled syringes. In addition, empty syringes, bulk containers, ampoules, and downstream finished products do not fall within the research boundaries after primary packaging. Also excluded are syringes in veterinary use or other non-therapeutic purposes such as laboratory use, since this research confines itself to prefilled syringes for human therapeutic drug delivery.

Prefilled Syringes Market Research Methodology

In order to ensure accurate estimates for the global prefilled syringes market size and forecast, Fact.MR uses a comprehensive research methodology, taking into account all aspects of the pharmaceutical delivery system ecosystem. Secondary sources such as company annual reports/SEC filings, FDA/EMA drug approval databases, clinical trial databases and registrations, pharmaceutical journals, and publications from industry experts have been considered as sources of information for this study. Some of the key points covered through secondary research include the market sizing by type of syringe (glass vs. polymer), type of prefilled syringes (single vs. dual chambered), therapeutic areas (biologics, vaccines, insulin, anticoagulants), and target end-users.

Secondary research findings have been validated with the help of a bottom-up strategy based on sales analysis of the leading syringe manufacturers, including their unit shipments, along with a top-down approach relying on macro factors like rise in adoption of biologics drugs, number of injectable drug approvals, increasing vaccination rates, prevalence of self-administration. The models developed for forecasting take into consideration the impact of rising trend towards biologics drugs, rising acceptance of safety-engineered syringes, and growing trend towards home-based medical care. Data triangulation techniques were adopted while analyzing both supply-side and demand-side data sets to enhance the accuracy of findings.

Primary / Field Interviews

It can be mentioned that around 130 primary interviews are being conducted throughout the period 2025-2026 covering various stakeholders involved in the value chain of the global prefilled syringes market. Among these respondents, around 30% comprised of syringe manufacturers and component suppliers, while another 30% consisted of pharmaceutical & biotechnology companies. Around 20% of the total respondents were from CDMOs and fill-finish services, along with 20% from regulatory experts, procurement heads of hospitals and clinicians. Interviewees were contacted across the geographic markets of North America, Europe, Asia Pacific, and few other emerging countries.